The Centers for Disease Control and Prevention warned the U.S. is at a “pivotal moment” in its battle to stem the momentum of the Delta variant. It currently makes up 83% of cases in the U.S.. (The Washington Post)

Following the approval of its controversial Alzheimer’s drug Aduhelm, Biogen is targeting consumers with an educational campaign on dementia and cognitive impairment. Critics are skeptical of the campaign, which includes a Facebook page and partnerships to expand locations for cognitive testing. (Kaiser Health News)

Google’s AI company DeepMind will open its database of 350,000 protein sequences and structures to researchers. “We hope, actually, that drug discovery and pharma will use it,” DeepMind CEO Demis Hassabis said. (Endpoints News)

New data from Israel show Pfizer’s COVID-19 vaccine is just 39% effective against the Delta variant. The results conflict with estimates from the U.K. showing the vaccine was 88% effective, and overall data show it is highly effective against hospitalization and severe illness. (CNBC Weekly)

Seres Therapeutics announced its ulcerative colitis drug failed to meet its primary endpoint in a Phase IIb study. The company will end two open label and maintenance studies. (STAT)